Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

From Solanezumab To Solithromycin: What To Watch For In Q4

Oct 11 2016

• By Alexandra Shimmings

Fireworks — • Source: Shutterstock

Related Content

Alnylam's 'Day After' Revusiran Failure Bad, Maybe Not Catastrophic

Oct 06 2016

Roche's Ocrelizumab Strengthens Lead In Primary Progressive MS

Feb 17 2016

Ocrelizumab Shines At ECTRIMS With Standout Data

Oct 13 2015

Sanofi/Regeneron's Sarilumab Faces Stiff Competition Despite Humira Triumph

Mar 12 2016

Lilly Awaits New Rewards For SGLT-2 Diabetes Drug Jardiance

Jul 27 2016

Rigel Optimistic On Fostamatinib Despite Narrow Phase III Benefit

Aug 30 2016

ICAAC 2015: Cempra CEO Sees Solithromycin Potential Beyond Infectious Diseases

Sep 22 2015

Alnylam, Medicines Company PCSK9 Drug Has Quarterly Dose Potential

Aug 30 2015

Beta amyloid market prospects still no clearer after AAIC analyses

Jul 22 2015

Gilead's New Hep B Treatment Shows Safety Benefit But Is It Enough?

Jan 06 2016

Xultophy Expands Label In Europe As First US Approval Decision Looms

Sep 05 2016

Heplisav-B Review Still On Track Even After Cancelled Advisory Cmte., Dynavax Says

Sep 06 2016

Related Companies

Eli Lilly and Company

Roche Holding AG

Genentech, Inc.

Regeneron Pharmaceuticals, Inc.

Sanofi

Boehringer Ingelheim GmbH

Johnson & Johnson

Novo Nordisk A/S

Acorda Therapeutics, Inc.

Alnylam Pharmaceuticals Inc.

Merck & Co., Inc.

Advanced Accelerator Applications SA

FUJIFILM Holdings Corp.

Melinta Therapeutics, Inc.

RedHill Biopharma Ltd.

Gilead Sciences, Inc.

Dynavax Technologies Corporation

GSK plc

Rigel Pharmaceuticals, Inc.

Synergy Pharmaceuticals, Inc.

Additional Topics

Research & Development Companies Clinical Trials Approvals Cardiovascular Infectious Diseases Inflammation Metabolic Disorders Neurology Cancer BioPharmaceutical

More from R&D

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window